Novartis Cancer-Drug Patent Denied by India Supreme Court

India’s Supreme Court denied Novartis AG’s request for patent protection for its Gleevec cancer treatment, allowing the nation’s generic-drug makers to continue to sell copies of the drug at a lower price.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.